Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Martin Shkreli: I'm not in contempt over drug industry ban

Published 02/10/2023, 04:53 PM
Updated 02/10/2023, 05:05 PM
© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli stands with his attorney Benjamin Brafman after exiting U.S. District Court upon being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Al

By Jonathan Stempel

NEW YORK (Reuters) - Martin Shkreli on Friday urged a U.S. judge not to hold him in civil contempt for failing to provide federal and state regulators with information to determine whether he is violating a lifetime ban from working in the pharmaceutical industry.

In a filing in Manhattan federal court, Shkreli said he has complied with the February 2022 ban "as extensively as possible and in good faith," and has provided the materials sought by the Federal Trade Commission (FTC) and seven states.

The ban also included a $64.6 million civil fine, which Shkreli said he is "so far unable" to pay. He said he intended to comply fully with the ban and provide requested information.

Spokespeople for the FTC did not immediately respond to requests for comment.

The FTC had accused Shkreli last month of failing to provide information about Druglike Inc, a company it said he formed last July.

In Friday's filing, Shkreli said he never had an ownership stake or executive role at Druglike, which he believed has been dissolved, and that he hoped to raise money for its successor DL Software, which he co-founded.

He also said Druglike and DL Software were "software companies creating professional software for chemists and physicists," and thus outside his pharmaceutical industry ban.

Shkreli became known as "pharma bro" after raising the price of the anti-parisitic drug Daraprim to $750 per tablet from $17.50 in 2015, and appearing unapologetic when criticized.

The lifetime ban related to Shkreli's efforts to keep generic versions of Daraprim off the market.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

U.S. District Judge Denise Cote, who imposed the ban and $64.6 million penalty, will decide the FTC contempt motion. The states joining the motion are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia.

Shkreli was sentenced to seven years in prison after being convicted in 2017 of defrauding investors in two hedge funds he ran, and scheming to defraud investors in the drugmaker Retrophin (NASDAQ:TVTX) Inc. He was released early from prison last May.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.